[go: up one dir, main page]

WO2018030881A3 - Use of thyroid hormone for treatment of choroidal disease - Google Patents

Use of thyroid hormone for treatment of choroidal disease Download PDF

Info

Publication number
WO2018030881A3
WO2018030881A3 PCT/KR2017/012501 KR2017012501W WO2018030881A3 WO 2018030881 A3 WO2018030881 A3 WO 2018030881A3 KR 2017012501 W KR2017012501 W KR 2017012501W WO 2018030881 A3 WO2018030881 A3 WO 2018030881A3
Authority
WO
WIPO (PCT)
Prior art keywords
thyroid hormone
treatment
choroidal disease
choroidal
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/012501
Other languages
French (fr)
Korean (ko)
Other versions
WO2018030881A2 (en
Inventor
윤성문
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2018030881A2 publication Critical patent/WO2018030881A2/en
Publication of WO2018030881A3 publication Critical patent/WO2018030881A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to a pharmaceutical composition containing a thyroid hormone for the prevention or treatment of a choroidal disease; a method for preventing or treating a choroidal disease by administering a thyroid hormone; and a novel use of a thyroid hormone for the prevention or treatment of a choroidal disease.
PCT/KR2017/012501 2017-01-03 2017-11-06 Use of thyroid hormone for treatment of choroidal disease Ceased WO2018030881A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2017-0000841 2017-01-03
KR1020170000841A KR101782577B1 (en) 2017-01-03 2017-01-03 Use of thyroid hormone for treatment of choroid disease

Publications (2)

Publication Number Publication Date
WO2018030881A2 WO2018030881A2 (en) 2018-02-15
WO2018030881A3 true WO2018030881A3 (en) 2018-03-29

Family

ID=60035899

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/012501 Ceased WO2018030881A2 (en) 2017-01-03 2017-11-06 Use of thyroid hormone for treatment of choroidal disease

Country Status (2)

Country Link
KR (1) KR101782577B1 (en)
WO (1) WO2018030881A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101782577B1 (en) * 2017-01-03 2017-09-28 윤성문 Use of thyroid hormone for treatment of choroid disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075032A (en) * 1995-02-01 2000-06-13 Allergan Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2006031922A2 (en) * 2004-09-15 2006-03-23 Ordway Research Institute Thyroid hormone analogs for promoting angiogenesis
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
KR101782577B1 (en) * 2017-01-03 2017-09-28 윤성문 Use of thyroid hormone for treatment of choroid disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075032A (en) * 1995-02-01 2000-06-13 Allergan Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
WO2006031922A2 (en) * 2004-09-15 2006-03-23 Ordway Research Institute Thyroid hormone analogs for promoting angiogenesis
WO2009122180A1 (en) * 2008-04-02 2009-10-08 Medical Research Council Pyrimidine derivatives capable of inhibiting one or more kinases
KR101782577B1 (en) * 2017-01-03 2017-09-28 윤성문 Use of thyroid hormone for treatment of choroid disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHI, L. Z.: "Use of Z310 cells as an in vitro blood-cerebrospinal fluid barrier model: Tight junction proteins and transport properties", TOXICOLOGY IN VITRO, vol. 22, no. 1, 28 July 2007 (2007-07-28), pages 190 - 199, XP022393682 *

Also Published As

Publication number Publication date
WO2018030881A2 (en) 2018-02-15
KR101782577B1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
MX2021004431A (en) Novel processes.
MX393855B (en) COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB
EP4223774A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
EA201691454A1 (en) COMPOSITIONS OF PRIDOPIDININE MODIFIED SHIPPING
WO2017022962A8 (en) Composition for preventing or treating immune disease, comprising ripk inhibitor as active ingredient
PH12019502577A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502095A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
PH12019502559A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
EP4445913A3 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
PH12022550448A1 (en) Niclosamide delayed-release composition and antiviral use thereof
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
MX2018009662A (en) Method and pharmaceutical composition for treatment of neurodegeneration.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)
WO2018030881A3 (en) Use of thyroid hormone for treatment of choroidal disease
PH12020550549A1 (en) Compositions for preventing or treating lupus
WO2017034242A3 (en) Novel catechol derivative and pharmaceutical composition comprising same
MX2019008603A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease.
MX2020005438A (en) Abuse deterrent morphine sulfate dosage forms.
ZA202202243B (en) Aqueous pharmaceutical composition of anti-pd1 antibody prolgolimab and the use thereof
PH12020551620A1 (en) Compositions for preventing or treating dry eye
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease
PH12020500120A1 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17839898

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17839898

Country of ref document: EP

Kind code of ref document: A2